AELIS.PA Aelis Farma EURONEXT up 28.40% intraday 27 Jan 2026: Volume spike note
AELIS.PA stock jumped 28.40% intraday to €1.56 on 27 Jan 2026 on EURONEXT. The move paired a price gap from the previous close of €1.22 with heavy volume at 106,388 shares, almost four times the average. Traders are watching Aelis Farma SA given its biotech pipeline and a clear short-term re-rating. We review intraday drivers, technicals, valuation, and quick forecasts to help traders parse today’s high-volume signal.
Intraday drivers for AELIS.PA stock
The immediate trigger was a large buy imbalance after market open. The stock opened at €1.47, hit a day high of €1.60, and printed strong block trades. Volume today is 106,388, versus an average of 27,605, giving a relative volume of 9.96. That level flags institutional or thematic flows rather than retail noise. News scanners show peer comparison posts on Investing.com and broader transcript access on Seeking Alpha.
Key fundamentals and what the numbers say about AELIS.PA stock
Aelis Farma reports EPS -0.60 and PE -2.41, reflecting current losses. Market cap is €19,698,590.00 with 13,632,242 shares outstanding. Price averages: 50-day €1.13, 200-day €1.15. Year range runs from €0.67 to €5.10. Cash per share is €0.79 and current ratio is 3.18, giving short-term liquidity cover. Research intensity shows R&D to revenue at 3.57x, typical for biotech development names.
Technical setup and trading signals for AELIS.PA stock
Momentum indicators show a short-term bullish tilt. RSI at 59.40 and CCI at 117.62 point to strength but near overbought levels. MACD is mildly positive. Bollinger middle band sits €1.11 and the day high of €1.60 is above the upper band. Money flow is strong with MFI at 78.04, confirming heavy buying. Traders should watch support near €1.41 and resistance near the 50-day average at €1.13 retested on pullbacks.
Meyka AI rates AELIS.PA with a score out of 100
Meyka AI rates AELIS.PA with a score out of 100: 60.81, Grade B, suggestion HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Company-level rating from market data shows C+ and a Sell recommendation dated 26 Jan 2026, highlighting valuation and profitability concerns. These grades are not guaranteed and are not financial advice.
Pipeline, catalysts and sector context for AELIS.PA stock
Aelis Farma is a biotech focused on CB1 signaling inhibitors, notably AEF0117 in Phase 2b. Clinical readouts and partnership updates are primary catalysts. The Healthcare sector on Europe exchanges is mixed YTD, with an average PE near 34.73, making small-cap biotech valuations volatile in this group. Positive trial news could rapidly re-rate AELIS.PA, while negative data would pressure the stock heavily.
Risks, liquidity and near-term trading strategy for AELIS.PA stock
Key risks include ongoing clinical development costs and negative earnings. Debt to equity is 1.13, and enterprise value sits at €15,797,590.00, showing leverage relative to market cap. Liquidity spiked today, which helps institutional execution, but average daily volume is 27,605, keeping normal liquidity thin. Traders should size positions with stop-loss discipline and avoid large exposure ahead of clinical milestones.
Final Thoughts
AELIS.PA stock’s intraday surge to €1.56 on 27 Jan 2026 combines a clear volume signal with biotech-specific catalysts. Today’s 106,388 share volume and relative volume near 9.96 suggest meaningful buyer interest. Fundamentals show losses with EPS -0.60 and a negative PE, while cash per share €0.79 gives runway for development. Meyka AI’s forecast model projects a monthly price of €1.66, implying 6.41% upside versus today’s price, and a quarterly model at €7.17, implying 359.62% upside. Forecasts are model-based projections and not guarantees. For traders focused on high-volume moves, monitor clinical updates, block trade prints, and whether volume sustains above average. Use tight risk controls given biotech binary outcomes and the mixed analyst ratings.
FAQs
Why did AELIS.PA stock spike today?
AELIS.PA stock spiked on heavy buying and large block trades after open. Volume hit 106,388, far above the 27,605 average. Market scanners also flagged peer comparisons and earnings-transcript interest on news platforms.
What are the main risks for AELIS.PA stock holders?
Main risks are clinical trial outcomes, continued losses with EPS -0.60, and thin typical liquidity. Analyst sentiment is mixed, and a failed readout would likely cause sharp declines.
What price targets or forecasts exist for AELIS.PA stock?
Meyka AI’s forecast model projects €1.66 monthly and €7.17 quarterly. The monthly projection implies 6.41% upside. Forecasts are model-based projections and not guarantees.
How should traders size positions in AELIS.PA stock after a volume spike?
Given the stock’s small market cap and binary biotech risk, use smaller position sizes and defined stops. High intraday volume helps execution but does not reduce clinical event risk.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
